DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Given Average Recommendation of “Hold” by Analysts

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) has been assigned an average rating of “Hold” from the fifteen research firms that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and three have assigned a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $14.4167.

XRAY has been the topic of several research analyst reports. Wells Fargo & Company lifted their price target on DENTSPLY SIRONA from $12.00 to $13.00 and gave the company an “equal weight” rating in a research report on Friday, February 27th. UBS Group decreased their target price on shares of DENTSPLY SIRONA from $17.00 to $16.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Zacks Research raised shares of DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a research report on Monday, March 2nd. Barclays started coverage on shares of DENTSPLY SIRONA in a report on Monday, December 8th. They set an “underweight” rating and a $12.00 price target on the stock. Finally, Mizuho upped their price target on shares of DENTSPLY SIRONA from $14.00 to $16.00 and gave the company a “neutral” rating in a research report on Monday, March 2nd.

DENTSPLY SIRONA Stock Performance

XRAY stock opened at $11.63 on Friday. The company has a 50-day simple moving average of $12.47 and a 200 day simple moving average of $12.14. The company has a market capitalization of $2.32 billion, a P/E ratio of -3.88, a PEG ratio of 1.37 and a beta of 0.99. The company has a quick ratio of 1.03, a current ratio of 1.51 and a debt-to-equity ratio of 1.50. DENTSPLY SIRONA has a fifty-two week low of $9.85 and a fifty-two week high of $17.18.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.01). The company had revenue of $961.00 million for the quarter, compared to analyst estimates of $926.40 million. DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.26 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Sell-side analysts predict that DENTSPLY SIRONA will post 1.84 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other DENTSPLY SIRONA news, Director Gregory T. Lucier purchased 15,000 shares of the stock in a transaction dated Monday, March 9th. The shares were acquired at an average price of $12.45 per share, for a total transaction of $186,750.00. Following the completion of the acquisition, the director owned 65,000 shares of the company’s stock, valued at $809,250. This represents a 30.00% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director James D. Forbes purchased 5,000 shares of the company’s stock in a transaction that occurred on Monday, March 9th. The shares were acquired at an average cost of $12.48 per share, for a total transaction of $62,400.00. Following the completion of the transaction, the director directly owned 10,000 shares of the company’s stock, valued at $124,800. This trade represents a 100.00% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought 70,000 shares of company stock valued at $956,437 in the last 90 days. Corporate insiders own 0.50% of the company’s stock.

Institutional Investors Weigh In On DENTSPLY SIRONA

Institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of DENTSPLY SIRONA in the 1st quarter valued at about $26,000. Goldman Sachs Group Inc. grew its position in DENTSPLY SIRONA by 827.3% during the first quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock valued at $36,378,000 after purchasing an additional 2,172,343 shares in the last quarter. Empowered Funds LLC grew its position in DENTSPLY SIRONA by 8.8% during the first quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock valued at $244,000 after purchasing an additional 1,320 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in DENTSPLY SIRONA by 7.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 593,021 shares of the medical instruments supplier’s stock valued at $8,860,000 after buying an additional 41,579 shares during the period. Finally, Focus Partners Wealth lifted its position in DENTSPLY SIRONA by 59.1% in the 1st quarter. Focus Partners Wealth now owns 25,181 shares of the medical instruments supplier’s stock worth $376,000 after buying an additional 9,355 shares in the last quarter. 95.70% of the stock is currently owned by institutional investors and hedge funds.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.